Christopher Breuer - New Albany OH, US Tarek Fahmy - New Haven CT, US Michael Simons - Hamden CT, US Pei-Yu Chen - East Haven CT, US Daniel Rowe Duncan - Boston MA, US Joseph Patterson - New Haven CT, US
Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGFβ inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.
Covermymeds Nov 2018 - Jun 2019
Interm Manager - Platform Operations
Covermymeds May 2017 - May 2019
Manager, Internal Infrastructure and Tier 2 Application Support
Covermymeds May 2017 - May 2019
Technical Product Owner - Infrastructure
Covermymeds Jul 1, 2016 - May 2017
Tier 2 Technical Specialist
The Ohio State University Apr 2012 - Dec 2014
It Systems Manager
Education:
The Ohio State University 1980 - 2011
Bachelors, Bachelor of Science, Business Management, Agriculture
Skills:
Leadership Public Speaking Information Technology Agile Methodologies Software Development Enterprise Architecture Collaboration Tools Vendor Management